Targets for molecular therapy in esophageal squamous cell carcinoma: An immunohistochemical analysis

Judith Boone, R. van Hillegersberg, G. J A Offerhaus, P. J. van Diest, I. H M Borel Rinkes, F. J W ten Kate

Research output: Contribution to journalArticle

Abstract

Neoadjuvant chemotherapy may improve the outcome of esophageal cancer after esophagectomy, but is accompanied by considerable toxicity by collateral destruction of normal cells. Such side effects may be avoided by developing therapies that specifically target molecular characteristics of tumors. The aim of the present study was to determine the proportion of esophageal squamous cell carcinoma (ESCC) patients that could possibly benefit from (a combination of) currently available targeted therapies, by assessing the frequency of immunohistochemical expression of their target molecular markers in ESCC tissues. Sections from a validated tissue microarray comprising 108 ESCCs were immunohistochemically stained for Bcl-2, c-KIT, cyclo-oxygenase-2 (COX-2), cyclin D1, estrogen receptor (ER), epidermal growth factor receptor (EGFR), Her-2/neu, progesterone receptor (PR), and vascular endothelial growth factor (VEGF). VEGF, cyclin D1, EGFR, and COX-2 could be detected in 55, 42, 40, and 40%, respectively. Her-2/neu, Bcl-2, and c-KIT were detected in 12, 11, and 10% of the tumors, respectively. No nuclear expression of ER or PR was noticed. Concurrent expression of two markers was noticed in 28% of ESCCs, whereas 25% of ESCCs showed concurrent expression of three markers. The concurrent expression of two of the most frequently expressed markers (VEGF, cyclin D1, EGFR, and COX-2) ranged from 11 (COX-2 and EGFR) to 26% (cyclin D1 and VEGF). The expression of all of these four markers was seen in 5% of ESCCs. Promising targets for molecular therapy in ESCC appear to be COX-2, VEGF, EGFR, and cyclin D1, as they are frequently overexpressed. Phase II clinical studies on these molecular markers may therefore be warranted. The role for targeted therapy against ER, PR, Her-2/neu, c-KIT, or Bcl-2 in ESCC seems limited.

Original languageEnglish (US)
Pages (from-to)496-504
Number of pages9
JournalDiseases of the Esophagus
Volume22
Issue number6
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Cyclin D1
Prostaglandin-Endoperoxide Synthases
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Progesterone Receptors
Estrogen Receptors
ErbB-2 Receptor
Therapeutics
Esophagectomy
Esophageal Neoplasms
Neoplasms
Esophageal Squamous Cell Carcinoma
Drug Therapy

Keywords

  • Esophageal cancer
  • Immunohistochemistry
  • Molecular therapy
  • Squamous cell carcinoma
  • Targeted therapy
  • Tissue microarray

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Boone, J., van Hillegersberg, R., Offerhaus, G. J. A., van Diest, P. J., Borel Rinkes, I. H. M., & ten Kate, F. J. W. (2009). Targets for molecular therapy in esophageal squamous cell carcinoma: An immunohistochemical analysis. Diseases of the Esophagus, 22(6), 496-504. https://doi.org/10.1111/j.1442-2050.2009.00951.x

Targets for molecular therapy in esophageal squamous cell carcinoma : An immunohistochemical analysis. / Boone, Judith; van Hillegersberg, R.; Offerhaus, G. J A; van Diest, P. J.; Borel Rinkes, I. H M; ten Kate, F. J W.

In: Diseases of the Esophagus, Vol. 22, No. 6, 2009, p. 496-504.

Research output: Contribution to journalArticle

Boone, J, van Hillegersberg, R, Offerhaus, GJA, van Diest, PJ, Borel Rinkes, IHM & ten Kate, FJW 2009, 'Targets for molecular therapy in esophageal squamous cell carcinoma: An immunohistochemical analysis', Diseases of the Esophagus, vol. 22, no. 6, pp. 496-504. https://doi.org/10.1111/j.1442-2050.2009.00951.x
Boone, Judith ; van Hillegersberg, R. ; Offerhaus, G. J A ; van Diest, P. J. ; Borel Rinkes, I. H M ; ten Kate, F. J W. / Targets for molecular therapy in esophageal squamous cell carcinoma : An immunohistochemical analysis. In: Diseases of the Esophagus. 2009 ; Vol. 22, No. 6. pp. 496-504.
@article{59734971c1a74fb286439d4e11472c73,
title = "Targets for molecular therapy in esophageal squamous cell carcinoma: An immunohistochemical analysis",
abstract = "Neoadjuvant chemotherapy may improve the outcome of esophageal cancer after esophagectomy, but is accompanied by considerable toxicity by collateral destruction of normal cells. Such side effects may be avoided by developing therapies that specifically target molecular characteristics of tumors. The aim of the present study was to determine the proportion of esophageal squamous cell carcinoma (ESCC) patients that could possibly benefit from (a combination of) currently available targeted therapies, by assessing the frequency of immunohistochemical expression of their target molecular markers in ESCC tissues. Sections from a validated tissue microarray comprising 108 ESCCs were immunohistochemically stained for Bcl-2, c-KIT, cyclo-oxygenase-2 (COX-2), cyclin D1, estrogen receptor (ER), epidermal growth factor receptor (EGFR), Her-2/neu, progesterone receptor (PR), and vascular endothelial growth factor (VEGF). VEGF, cyclin D1, EGFR, and COX-2 could be detected in 55, 42, 40, and 40{\%}, respectively. Her-2/neu, Bcl-2, and c-KIT were detected in 12, 11, and 10{\%} of the tumors, respectively. No nuclear expression of ER or PR was noticed. Concurrent expression of two markers was noticed in 28{\%} of ESCCs, whereas 25{\%} of ESCCs showed concurrent expression of three markers. The concurrent expression of two of the most frequently expressed markers (VEGF, cyclin D1, EGFR, and COX-2) ranged from 11 (COX-2 and EGFR) to 26{\%} (cyclin D1 and VEGF). The expression of all of these four markers was seen in 5{\%} of ESCCs. Promising targets for molecular therapy in ESCC appear to be COX-2, VEGF, EGFR, and cyclin D1, as they are frequently overexpressed. Phase II clinical studies on these molecular markers may therefore be warranted. The role for targeted therapy against ER, PR, Her-2/neu, c-KIT, or Bcl-2 in ESCC seems limited.",
keywords = "Esophageal cancer, Immunohistochemistry, Molecular therapy, Squamous cell carcinoma, Targeted therapy, Tissue microarray",
author = "Judith Boone and {van Hillegersberg}, R. and Offerhaus, {G. J A} and {van Diest}, {P. J.} and {Borel Rinkes}, {I. H M} and {ten Kate}, {F. J W}",
year = "2009",
doi = "10.1111/j.1442-2050.2009.00951.x",
language = "English (US)",
volume = "22",
pages = "496--504",
journal = "Diseases of the Esophagus",
issn = "1120-8694",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Targets for molecular therapy in esophageal squamous cell carcinoma

T2 - An immunohistochemical analysis

AU - Boone, Judith

AU - van Hillegersberg, R.

AU - Offerhaus, G. J A

AU - van Diest, P. J.

AU - Borel Rinkes, I. H M

AU - ten Kate, F. J W

PY - 2009

Y1 - 2009

N2 - Neoadjuvant chemotherapy may improve the outcome of esophageal cancer after esophagectomy, but is accompanied by considerable toxicity by collateral destruction of normal cells. Such side effects may be avoided by developing therapies that specifically target molecular characteristics of tumors. The aim of the present study was to determine the proportion of esophageal squamous cell carcinoma (ESCC) patients that could possibly benefit from (a combination of) currently available targeted therapies, by assessing the frequency of immunohistochemical expression of their target molecular markers in ESCC tissues. Sections from a validated tissue microarray comprising 108 ESCCs were immunohistochemically stained for Bcl-2, c-KIT, cyclo-oxygenase-2 (COX-2), cyclin D1, estrogen receptor (ER), epidermal growth factor receptor (EGFR), Her-2/neu, progesterone receptor (PR), and vascular endothelial growth factor (VEGF). VEGF, cyclin D1, EGFR, and COX-2 could be detected in 55, 42, 40, and 40%, respectively. Her-2/neu, Bcl-2, and c-KIT were detected in 12, 11, and 10% of the tumors, respectively. No nuclear expression of ER or PR was noticed. Concurrent expression of two markers was noticed in 28% of ESCCs, whereas 25% of ESCCs showed concurrent expression of three markers. The concurrent expression of two of the most frequently expressed markers (VEGF, cyclin D1, EGFR, and COX-2) ranged from 11 (COX-2 and EGFR) to 26% (cyclin D1 and VEGF). The expression of all of these four markers was seen in 5% of ESCCs. Promising targets for molecular therapy in ESCC appear to be COX-2, VEGF, EGFR, and cyclin D1, as they are frequently overexpressed. Phase II clinical studies on these molecular markers may therefore be warranted. The role for targeted therapy against ER, PR, Her-2/neu, c-KIT, or Bcl-2 in ESCC seems limited.

AB - Neoadjuvant chemotherapy may improve the outcome of esophageal cancer after esophagectomy, but is accompanied by considerable toxicity by collateral destruction of normal cells. Such side effects may be avoided by developing therapies that specifically target molecular characteristics of tumors. The aim of the present study was to determine the proportion of esophageal squamous cell carcinoma (ESCC) patients that could possibly benefit from (a combination of) currently available targeted therapies, by assessing the frequency of immunohistochemical expression of their target molecular markers in ESCC tissues. Sections from a validated tissue microarray comprising 108 ESCCs were immunohistochemically stained for Bcl-2, c-KIT, cyclo-oxygenase-2 (COX-2), cyclin D1, estrogen receptor (ER), epidermal growth factor receptor (EGFR), Her-2/neu, progesterone receptor (PR), and vascular endothelial growth factor (VEGF). VEGF, cyclin D1, EGFR, and COX-2 could be detected in 55, 42, 40, and 40%, respectively. Her-2/neu, Bcl-2, and c-KIT were detected in 12, 11, and 10% of the tumors, respectively. No nuclear expression of ER or PR was noticed. Concurrent expression of two markers was noticed in 28% of ESCCs, whereas 25% of ESCCs showed concurrent expression of three markers. The concurrent expression of two of the most frequently expressed markers (VEGF, cyclin D1, EGFR, and COX-2) ranged from 11 (COX-2 and EGFR) to 26% (cyclin D1 and VEGF). The expression of all of these four markers was seen in 5% of ESCCs. Promising targets for molecular therapy in ESCC appear to be COX-2, VEGF, EGFR, and cyclin D1, as they are frequently overexpressed. Phase II clinical studies on these molecular markers may therefore be warranted. The role for targeted therapy against ER, PR, Her-2/neu, c-KIT, or Bcl-2 in ESCC seems limited.

KW - Esophageal cancer

KW - Immunohistochemistry

KW - Molecular therapy

KW - Squamous cell carcinoma

KW - Targeted therapy

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=69249123371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249123371&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2050.2009.00951.x

DO - 10.1111/j.1442-2050.2009.00951.x

M3 - Article

C2 - 19302210

AN - SCOPUS:69249123371

VL - 22

SP - 496

EP - 504

JO - Diseases of the Esophagus

JF - Diseases of the Esophagus

SN - 1120-8694

IS - 6

ER -